Olumiant

Showing 5 posts of 5 posts found.

shutterstock_243110086

Lilly & Incyte’s Olumiant hits main goal in atopic dermatitis

January 28, 2020
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, pharma

Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing …

shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019
Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …

lilly_building_with_american_flag_web

Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

February 5, 2019
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …

lilly_building_with_american_flag_web

FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats

June 5, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

June 30, 2017
Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …

Latest content